HC Wainwright Has Negative Forecast for UBX FY2026 Earnings

Unity Biotechnology, Inc. (NASDAQ:UBX) – Analysts at HC Wainwright reduced their FY2026 earnings per share estimates for Unity Biotechnology in a report released on Monday, March 24th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.65) per share for the year, down from their prior estimate of ($0.42). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2027 earnings at ($0.09) EPS, FY2028 earnings at $0.25 EPS and FY2029 earnings at $0.40 EPS.

Separately, Chardan Capital decreased their price target on Unity Biotechnology from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday.

Unity Biotechnology Trading Down 3.4 %

Shares of UBX stock opened at $1.14 on Thursday. The company’s 50-day moving average price is $1.87 and its 200-day moving average price is $1.51. The stock has a market cap of $19.23 million, a price-to-earnings ratio of -0.87 and a beta of 1.02. Unity Biotechnology has a twelve month low of $0.94 and a twelve month high of $3.10.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC grew its holdings in Unity Biotechnology, Inc. (NASDAQ:UBX) by 9.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 163,242 shares of the company’s stock after acquiring an additional 14,199 shares during the quarter. Geode Capital Management LLC owned about 0.97% of Unity Biotechnology worth $240,000 at the end of the most recent reporting period. 29.49% of the stock is owned by institutional investors and hedge funds.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.